單株抗體療法的未來：抗體技術革新與擴大策略及2011年前的預測

單株抗體療法的未來：抗體技術革新與擴大策略及2011年前的預測 是由出版商Business Insights在2006年07月所出版的。 這份英文市場調查報告書價格從美金2875起跳。

簡介

目錄

Abstract

The monoclonal antibody (mAb) market has grown rapidly in recent years, reaching sales of $14bn in 2005, an increase of 36.5% from 2004 sales of $10.3bn. Köhler and Milstein developed the hybridoma method of murine antibody production in 1975, which allowed the production of the first mAb to market; Johnson & Johnson's Orthoclone OKT3 (muromonab) in 1986. The mAb market is highly innovative and a key trend has been the move from murine to humanized and fully human antibodies. As technology has progressed these humanized mAbs have prevented immune responses (HAMA), thus having a larger market potential. The traditional therapy areas in the mAb market are oncology and autoimmune and inflammatory disorders (AIID), however this is forecast to change with the emergence of other therapy areas including infectious disease and ophthalmology. The clear leader in the mAb market is Genentech with 5 marketed drugs, with sales totaling $4,116.4m in 2005. A key theme of this report is the high level of innovation, as demonstrated by advancements in antibody engineering with the introduction of chimeric, humanized and fully human mAbs. Other innovation in antibody technology include advancements in non-invasive drug delivery technology, which is predicted to lead to a huge boost in sales in the long-term once drugs that utilize this technology come to market.

Table of Contents

Executive Summary

• Introduction
• Antibody engineering and innovation in the market
• The current monoclonal antibody market
• The antibody pipeline and forecasts to 2011
• Competitive landscape and future growth strategies

Chapter 1 Introduction

• Summary
• Introduction
• History of monoclonal antibodies
• Monoclonal antibody approval process
• Current approval process
• Biogeneric regulations
• Key trends in the market
• Advancements in innovation
• Diversification of therapy areas
• Big Pharma entering the mAb market

Chapter 2 Antibody engineering and innovation in the market

• Summary
• Introduction
• The move from murine to fully human mAbs
• Whole IgG monoclonal antibodies
  • Murine
  • Chimeric
  • Humanized
  • Human
• Innovations in antibody structures
  • Fab fragments
  • Single chain variable fragments
• Extended release formulations
• Innovation in antibody conjugation
• Types of conjugation
  • Direct arming: antibody conjugation
  • Indirect arming: Bispecific monoclonal antibodies
  • Pre-targeting
• Marketed conjugated monoclonal antibodies
• Conjugation technology
  • Seattle Genetics antibody technology
  • ImmunoGen mAb technology
  • Peregrine mAb technology
• Enhancing monoclonal antibody potency
• Drug discovery
• Cambridge Antibody Technology
• Dyax
• Morphosys
• Innovation in drug delivery
• Drug delivery devices
• Inhaled monoclonal antibodies
• Oral monoclonal antibodies

Chapter 3 The current monoclonal antibody market

• Summary
• Introduction
• Strategic analysis
• Drivers
  • Pipeline drugs
  • Immature market
  • Big Pharma entering the mAb market
  • High level of innovation
  • Approval of new indications
  • Combination therapies
• Resistors
  • Publicized side effects
  • Drugs suspended from market
  • Competition from small molecule drugs
  • Pricing and reimbursement schemes
• Analysis of launched drugs
• Oncology
  • Rituxan
  • Herceptin
  • Avastin
  • Erbitux
  • Campath
  • Zevalin
  • MyloTarg
  • Bexxar
• AIID
  • Remicade
  • Humira
  • Raptiva
  • Simulect
  • Zenapax
  • OrthoClone OKT3
• Hemostasis
  • ReoPro
• Anti-infectives
  • Synagis
• Respiratory
  • Xolair
• Marketed monoclonal antibody forecasts

Chapter 4 The antibody pipeline and forecasts to 2011

• Summary
• Introduction
• Strategic analysis
• Opportunities
• Clinical trials
  • Erbitux and Avastin
  • Simulect, Zenapax and Campath
  • Campath
  • Others
• Innovation in antibody engineering
• New indications
• Challenges
• Generic biologics
• Adverse reactions in clinical trials, side effects and termination of
• development
• High attrition rates
• Analysis of pipeline drugs
• AIID
  • Cimzia
  • MRA/Actemra
  • Eculizumab
  • AMG-162
• Cardiovascular
  • Pexelizumab
• Infectious diseases
  • Numax
• Oncology
  • ABX-EGF
  • MDX-010+MDX-1379
  • Humax
• Ophthalmology
  • Lucentis
• Late stage pipeline forecasts
• The antibody market in 2011

Chapter 5 Competitive landscape and future growth strategies

• Summary
• Introduction
• Key players in the monoclonal antibody market
• M&A and licensing activity
• Big Pharma acquiring biotechs and antibody companies
  • AstraZeneca and CAT
  • Novartis and NeuTec
  • Amgen and Abgenix
  • Roche and GlycArt
  • MedImmune and Cellective Therapeutics
  • Pfizer and Bioren
• Company profiles
• Big Pharma
• Roche
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline
• Novartis
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline
• Pfizer
  • Company overview
  • Strategic and growth analysis
  • Pipeline
• Large biotech
• Genentech
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline
• MedImmune
  • Company Profile
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• Biogen Idec
  • Company overview
  • Strategic analysis
  • Marketed products
  • Pipeline products
• UCB-Celltech
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• Small biotech/antibody companies
• Medarex
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• XOMA
  • Company overview
  • Strategic and growth analysis
  • Marketed products
  • Pipeline products
• Technology companies
• BioWa
  • Company overview
  • Strategic and growth analysis
  • Pipeline products
• Crucell
  • Company overview
  • Strategic and growth analysis
  • Pipeline products

Chapter 6 Appendix

• Sales data
• Index

相關商品

抗體和免疫相關市場調查報告書

大腸癌、血管增生、抗體分析
Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

白血病、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Leukemia, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

淋巴癌、血管增生、抗體：藥劑開發策略分析
Triple Analysis: Lymphoma, Angiogenesis and Antibodies
價格 : US $ 5175
出版日期 : 2012年01月

Business Insights發行的生物科技相關市場調查報告書

生化科技的先進地區叢集與新興地區叢集

Established and Emerging Biotech Clusters

價格 : US $ 4795

出版日期 : 2011年09月

次世代蛋白質・肽治療藥

Next-Generation Protein and Peptide Therapeutics

價格 : US $ 3835

出版日期 : 2011年08月

至2016年的免疫調節劑市場展望

The Immunomodulators Market Outlook to 2016

價格 : US $ 3835

出版日期 : 2011年08月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!